Atherosclerosis Pipeline Review | Latest Drug Approvals, Novel and Emerging Therapies, Clinical Trials, and Treatment Outlook | GSK, Amgen, Novo Nordisk, Hoffmann-La Roche, Daiichi Sankyo, Genentech

Atherosclerosis Pipeline Review | Latest Drug Approvals, Novel and Emerging Therapies, Clinical Trials, and Treatment Outlook | GSK, Amgen, Novo Nordisk, Hoffmann-La Roche, Daiichi Sankyo, Genentech
(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Atherosclerosis pipeline constitutes 25+ key companies continuously working towards developing 25+ Atherosclerosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Atherosclerosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Atherosclerosis Pipeline Insight, 2023 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Atherosclerosis Market.

 

Some of the key takeaways from the Atherosclerosis Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Atherosclerosis treatment therapies with a considerable amount of success over the years. 
  • Atherosclerosis companies working in the treatment market are ImmunoPrecise Antibodies, Afimmune, Verve Therapeutics, Silence Therapeutics, Merck Sharp & Dohme LLC, Regio Bioscience, Amgen, Novo Nordisk, Hoffmann-La Roche, Daiichi Sankyo, Inc., Kowa Research Institute, Inc., Genentech, Inc., Omicron Pharmaceuticals, Novo Nordisk A/S, GlaxoSmithKline, Sanofi, Tallikut Pharmaceuticals, Inc., and others, are developing therapies for the Atherosclerosis treatment 
  • Emerging Atherosclerosis therapies in the different phases of clinical trials are- TATX-21, Epeleuton, VERVE-101, SLN360, MK-0616, REG-001, Olpasiran, Ziltivekimab, Evolocumab, DL-alpha-tocopherol, Olmesartan medoxomil, K-604, MLDL1278A, Ateronon, NNC0385-0434, LOSMAPIMOD 7.5 MG, Ramipril, VIA-2291, and others are expected to have a significant impact on the Atherosclerosis market in the coming years.   
  • In December 2022, Amgen will begin a double-blind, multi-center, randomised, placebo-controlled research to evaluate the effect of olpasiran on major cardiovascular events in patients with atherosclerotic cardiovascular disease and elevated lipoprotein(a)

 

Atherosclerosis Overview

About 50% of deaths in westernised societies are attributable to atherosclerosis, a chronic inflammatory disease of the arteries.

 

Get a Free Sample PDF Report to know more about Atherosclerosis Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/atherosclerosis-pipeline-insight

 

Emerging Atherosclerosis Drugs Under Different Phases of Clinical Development Include:

  • TATX-21: ImmunoPrecise Antibodies
  • Epeleuton: Afimmune
  • VERVE-101: Verve Therapeutics
  • SLN360: Silence Therapeutics
  • MK-0616: Merck Sharp & Dohme LLC
  • REG-001: Regio Bioscience
  • Aloricumab: Sanofi/ Regeneron
  • VB 201: VBL therapeutics
  • Olpasiran: Amgen
  • Ziltivekimab: Novo Nordisk
  • Evolocumab: Amgen
  • DL-alpha-tocopherol: Hoffmann-La Roche
  • Olmesartan medoxomil: Daiichi Sankyo, Inc.
  • K-604: Kowa Research Institute, Inc.
  • MLDL1278A: Genentech, Inc.
  • Ateronon: Omicron Pharmaceuticals
  • NNC0385-0434: Novo Nordisk A/S
  • LOSMAPIMOD 7.5 MG: GlaxoSmithKline
  • Ramipril: Sanofi
  • VIA-2291: Tallikut Pharmaceuticals, Inc.

 

Route of Administration

Atherosclerosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical.
  • Molecule Type

 

Molecule Type

Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

 

Atherosclerosis Pipeline Therapeutics Assessment

  • Atherosclerosis Assessment by Product Type
  • Atherosclerosis By Stage and Product Type
  • Atherosclerosis Assessment by Route of Administration
  • Atherosclerosis By Stage and Route of Administration
  • Atherosclerosis Assessment by Molecule Type
  • Atherosclerosis by Stage and Molecule Type

 

DelveInsight’s Atherosclerosis Report covers around 25+ products under different phases of clinical development like-

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further Atherosclerosis product details are provided in the report. Download the Atherosclerosis pipeline report to learn more about the emerging Atherosclerosis therapies

 

Some of the key companies in the Atherosclerosis Therapeutics Market include:

Key companies developing therapies for Atherosclerosis are – F. Hoffmann-La Roche Ltd., Mylan N.V., Teva Pharmaceutical Industries Ltd., Sanofi, Pfizer Inc., GlaxoSmithKline plc, Novartis AG, Merck & Co., Inc, Allergan, AstraZeneca, Johnson & Johnson Private Limited, Hikma Pharmaceuticals PLC, Bristol-Myers Squibb Company, Bayer AG, Boehringer Ingelheim International GmbH., Dr. Reddy’s Laboratories Ltd., Gilead Sciences, Inc., Amgen Inc., Eli Lilly and Company, AbbVie Inc., Lupin, Allergan, and others.

 

Atherosclerosis Pipeline Analysis:

The Atherosclerosis pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Atherosclerosis with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Atherosclerosis Treatment.
  • Atherosclerosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Atherosclerosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Atherosclerosis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Atherosclerosis drugs and therapies

 

Atherosclerosis Pipeline Market Drivers

  • Rising prevalence of cardiovascular diseases, growing number of geriatric population, increase in the number of research and development activities are some of the important factors that are fueling the Atherosclerosis Market.

 

Atherosclerosis Pipeline Market Barriers

  • However, high cost associated with the treatment, lack of awareness among people and other factors are creating obstacles in the Atherosclerosis Market growth.

 

Scope of Atherosclerosis Pipeline Drug Insight    

  • Coverage: Global
  • Key Atherosclerosis Companies: ImmunoPrecise Antibodies, Afimmune, Verve Therapeutics, Silence Therapeutics, Merck Sharp & Dohme LLC, Regio Bioscience, Amgen, Novo Nordisk, Hoffmann-La Roche, Daiichi Sankyo, Inc., Kowa Research Institute, Inc., Genentech, Inc., Omicron Pharmaceuticals, Novo Nordisk A/S, GlaxoSmithKline, Sanofi, Tallikut Pharmaceuticals, Inc., and others
  • Key Atherosclerosis Therapies: TATX-21, Epeleuton, VERVE-101, SLN360, MK-0616, REG-001, Olpasiran, Ziltivekimab, Evolocumab, DL-alpha-tocopherol, Olmesartan medoxomil, K-604, MLDL1278A, Ateronon, NNC0385-0434, LOSMAPIMOD 7.5 MG, Ramipril, VIA-2291, and others
  • Atherosclerosis Therapeutic Assessment: Atherosclerosis current marketed and Atherosclerosis emerging therapies
  • Atherosclerosis Market Dynamics: Atherosclerosis market drivers and Atherosclerosis market barriers 

 

Request for Sample PDF Report for Atherosclerosis Pipeline Assessment and clinical trials

 

Table of Contents

1

Atherosclerosis Report Introduction

2

Atherosclerosis Executive Summary

3

Atherosclerosis Overview

4

Atherosclerosis- Analytical Perspective In-depth Commercial Assessment

5

Atherosclerosis Pipeline Therapeutics

6

Atherosclerosis Late Stage Products (Phase II/III)

7

Atherosclerosis Mid Stage Products (Phase II)

8

Atherosclerosis Early Stage Products (Phase I)

9

Atherosclerosis Preclinical Stage Products

10

Atherosclerosis Therapeutics Assessment

11

Atherosclerosis Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Atherosclerosis Key Companies

14

Atherosclerosis Key Products

15

Atherosclerosis Unmet Needs

16 

Atherosclerosis Market Drivers and Barriers

17

Atherosclerosis Future Perspectives and Conclusion

18

Atherosclerosis Analyst Views

19

Appendix

20

About DelveInsight

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

 

About DelveInsight

 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services


Posted

in

by

Tags: